The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Resource: Utilizing Samples from the Arizona Parkinson’s Di, 2012Preferential Loss of Serotonin Axon Subtypes in Depression in Parkinson's Disease
Objective/Rationale:
Depression occurs in Parkinson’s disease (PD) much more frequently than in the general population, and is a major factor contributing to decreased quality of life for affected... -
MJFF Research Grant, 2012Network Biomarkers for the Assessment of Parkinson's Disease: A Multi-modal Optimization Study
Objective/Rationale:
This study will compare positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) for measuring the activity of Parkinson's disease-specific brain... -
Rapid Response Innovation Awards, 2012Development of an HTS Assay to Break the Alpha-Synuclein-Glucocerebrosidase Feedback Loop
Objective/Rationale:
We aim to develop a novel screening platform to identify candidate drugs to treat Parkinson’s disease. The screening platform incorporates the link between alpha... -
LRRK2 in the Immune System, 2012Does Peripheral Immune Challenge Exacerbate LRRK2-Induced Neuronal Pathology?
Objective/Rationale:
Neuro-immune interactions may have etiological roles in the development of several neurodegenerative disorders. LRRK2 is a cell signaling protein and when mutated, is... -
LRRK2 in the Immune System, 2012Clinical Evaluation of LRRK2 Inhibitors on Inflammatory Responses in Crohn's and Parkinson's Diseases
Objective/Rationale:
Leucine-rich repeat kinase 2 (LRRK2) is genetically associated with several human diseases, including Parkinson’s disease (PD) and Crohn’s disease (CD). Recent... -
Dyskinesia Challenge, 2012Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia
Objective/Rationale:
Amantadine is currently the only available medication to treat levodopa-induced dyskinesia: involuntary, jerky movements caused by long-term use of the Parkinson’s drug levodopa...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.